To evaluate the tolerability and preliminary effects of a DPP4 inhibitor (sitagliptin) and an SGLT2 inhibitor (dapagliflozin) in patients with Parkinson's disease (PD) or Dementia with Lewy Bodies (DLB), focusing on primary outcomes such as MDS-UPDRS scores and cognitive function.
Key Findings:
Both sitagliptin and dapagliflozin were well-tolerated with no adverse events.
Significant differences were observed in MDS-UPDRS part 1 (P = 0.008), part 2 (P = 0.047), and total scores (P = 0.020) among the groups.
The dapagliflozin group showed more favorable trends in MDS-UPDRS scores, while cognitive function changes did not reach significance.
Interpretation:
The pilot study suggests that DPP4 and SGLT2 inhibitors are safe for patients with PD and DLB, with dapagliflozin showing potential symptomatic benefits, warranting further investigation into its therapeutic implications.
Limitations:
Small study size and short duration.
Most participants had PD, with only one subject having DLB.
Potential biases or confounding factors affecting the results should be considered.
Conclusion:
Preliminary findings indicate the need for larger-scale, long-term studies to confirm potential benefits and explore disease-modifying effects, particularly in the context of existing treatment options.
